Determining clinically meaningful decline in preclinical Alzheimer disease
Neurology® Podcast · Sharon Quimby
July 22, 201921m 25s
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In the first segment, Dr. Gregory Day talks with Dr. Philip Insel about his paper on determining clinically meaningful decline in preclinical Alzheimer disease. In the second part of the podcast, Dr. Sarah Tabrizi talks about targeting Huntington expression in patients with Huntington's disease in her interview with Dr. Jeffrey Ratliff. Read Dr. Tabrizi's paper in NEJM: https://www.nejm.org/doi/full/10.1056/NEJMoa1900907?query=recirc_curatedRelated_article.